Background: Failure to detect depression in patients with Parkinson disease (PD) can lead to worsened outcomes for patients and caregivers. Accurate identification of depression would enable practitioners to provide comprehensive care for their patients with PD.
An accurate way of detecting those patients with PD at risk for depression is highly desirable for clinicians, and would help appropriately target scarce front-line mental health resources. 10, 11 The current diagnostic gold standard for depression is the criterion-based clinical interview. However, in nonresearch settings this method is impractical for detecting depression. 8, 10 Consequently, depression screening tools are used to identify patients requiring further assessment and are a key first step to diagnosis. There are many tools available for depression screening in PD; however, it is unclear which of these tools is most accurate. [9] [10] [11] [12] Narrative reviews exist on this topic but a systematic review for examining tools for detecting depression in PD was not identified. 11, 13 The objective of this study was to review the diagnostic accuracy of screening tools for the detection of depression in adult outpatients with PD. We also sought to determine whether there were any reported differences in the administration of depression screening tools.
METHODS Our study methods were determined a priori and registered with PROSPERO (CRD42014014503). 14 The study protocol follows the recommendations provided in the Cochrane Handbook for Diagnostic Test Accuracy 15, 16 and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols Statement and guidelines. 17, 18 Search strategy and literature sources. We searched MEDLINE, EMBASE, and PsycINFO from database inception to December 1, 2015, without restrictions on year or language. Controlled vocabulary was used for the 3 main clusters of PD, depression, and detection. Related keywords, MeSH, EMTREE, and PsycINFO terms were combined with "or" to create search themes which were then combined with "and" (box e-1 on the Neurology ® Web site at Neurology.org). Gray literature sources were reviewed (search date: November 24-28, 2014), including conference abstracts, society, and guideline Web sites (figure 1).
Study screening and selection. All citations and full-text articles were independently reviewed by 2 authors (Z.G., K.J.M.).
If disagreement occurred, it was resolved by discussion. Eligibility criteria for the abstract review stage included the following: adults with PD and administration of a depression screening tool. Full-text eligibility criteria included diagnostic accuracy studies involving adults with PD in an outpatient setting (i.e., long-term care, assisted, or community living), the use of a depression screening tool as an index test to identify depression cases, and a gold standard. The gold standards accepted were the DSM 19 or ICD. Studies were excluded if they lacked sufficient data for extraction or analysis, were unavailable in full text, or were nonhuman or not original research. We also consulted with field experts (N.J., T.P., J. Quickfall) to identify additional works. The kappa statistic was used to determine agreement between reviewers on study selection at the abstract review stage.
Data extraction. A data extraction sheet was used to record study and patient demographic variables, PD severity, dementia status, study-specific prevalence of depression, index screening test, gold or referent standard, sensitivity, specificity, predictive values, and likelihood ratios. Data were extracted and verified between 2 authors (Z.G., K.J.M.). When multiple publications were based on the same population, the study with the largest sample was chosen. Investigators contacted authors to clarify potential overlap in cases where uncertainty existed. We only included unique, nonoverlapping samples to avoid multiple publication bias. 5, 20 Risk of bias and methodologic quality assessment. The Quality Assessment of Diagnostic Accuracy Studies-(QUADAS-2) tool 21 was used to assess methodologic quality and risk of bias. The tool was completed in duplicate for each included study (Z.G., K.J.M.). All items within the QUADAS-2 tool were reported in 22 items after investigators collapsed 4 selfevident items together.
Data synthesis, extraction, and analyses. Two main outcomes were assessed: an estimate of pooled prevalence and the pooled diagnostic accuracy measures for depression screening tools.
Pooled prevalence. An estimate of pooled prevalence for major or major and minor depression in patients with PD was calculated from study-specific point estimates using Mantel-Haenszel-weighted DerSimonian and Laird models. 22 Heterogeneity in pooled estimates was assessed using I 2 statistic and assessment of the p value associated with the Cochran Q statistic. Inspection of forest plots and the I 2 statistic were used to assess for heterogeneity. A p value of ,0.05 was used to determine significance. Heterogeneity was stratified as low, moderate, substantial, or considerable (0%-40%, 30%-60%, 50%-90%, or .75%, respectively). 20 Where heterogeneity was detected, subgroup analysis and univariate metaregression were attempted. Covariates were identified as dementia status, disease severity, clinical setting, and interview type. 5 Pooled estimates. Individual 2 3 2 contingency tables were extracted and calculated from reported study-specific sensitivity, specificity, positive and negative predictive values, positive likelihood ratio (PLR) and negative likelihood ratio (NLR), and sample sizes. Zero cells were continuity corrected by adding 1.0 to each cell. Where necessary, values were back calculated from original reports and rounded to the nearest whole number for analysis. All available cutoff points were extracted for each depression screening tool. We first pooled across the optimal cutoffs reported in each study. These cutoffs may not have been the same between studies. Where possible, data were pooled across the same cutoff for a tool. When data discrepancies arose within a manuscript, authors were contacted. If data verification was not possible, those studies were excluded. This occurred in 2 studies involving 2 different tools (5-item WHO Well-Being Index and Depression Screening in Parkinson's disease questionnaire) where data inconsistencies existed between the text and tables. 23, 24 Pooled sensitivity, specificity, and likelihood ratios were calculated using bivariate random-effects models. 25 The bivariate random-effects model was chosen to account for the frequent negative bivariate correlation between sensitivity and specificity. For analysis, these models require .4 studies to compute metaanalyses (midas, metandi). These bivariate models also examine the proportion of heterogeneity attributable to threshold effects. This indicates how much of the variation between studies is accounted for by differences in cutoff points. For the cutoff analyses, if only 3 studies were present, we combined estimates using DerSimonian and Laird random-effects models.
Summary receiver operating characteristic (SROC) plots were generated for all tools that were pooled to examine the changes in sensitivity and specificity values as the thresholds varied between studies. 16 These plots examine test accuracy taking into account the different thresholds or cutoffs used across studies. 16 More discriminatory tests generate SROC plots that are centered at the top left of the plane or with a higher area under the curve (AUC). 16 To examine the posttest probabilities, a Fagan plot was created for each of the meta-analyzed tools. The calculated prevalence from included studies was used for pretest probability. Analyses were conducted using STATA 13.1 (Stata Corp., College Station, TX).
RESULTS
The electronic database search strategy yielded 7,177 citations. Most studies were excluded at the screening stage because they did not examine the diagnostic accuracy of depression screening tools in patients with PD. A total of 21 studies were retained for qualitative synthesis and 15 for meta-analysis (figure 1). Screening concordance between investigators for study inclusion was good (k 5 0.68; 95% confidence interval [CI] 0.61-0.76). 26 The gray literature search generated 1,007 citations (figure 1).
Risk of bias assessment. While quality scores did not lead to the removal of any studies from the review, there were concerns related to the reporting of blinding (table e-1). Blinding was generally not clearly stated; and investigators were unclear about index-referent and referent-index. The lack of clarity around blinding appeared likely attributable to unclear reporting vs design-related factors.
Summary of included studies. Overall, 21 studies including 15 unique study populations and 2,028 patients with PD were included (table 1). The mean age of participants was 67.2 years (95% CI 65.1-69.4). All included studies were in English, published between 2000 and 2014, with broad geographic representation across 10 countries (Argentina, Australia, Brazil, Ecuador, Germany, Netherlands, Sri Lanka, Turkey, United Kingdom, United States). Included diagnostic accuracy studies comprised consecutive series, direct comparison, Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram 40 overlaps with the samples in Leentjens et al. 41 and Naarding et al., 37 which all review MADRS and HDRS as these represent a continuous sample from a cohort. Only the largest sample 52 was included in the table and meta-analysis.
and cross-sectional diagnostic test accuracy designs, 27 with the exception of 2 cohort studies. 28, 29 There were a total of 5 multicenter and 10 single-center studies (one study was unclear), and the study settings were movement disorder (n 5 11) or neurology clinics (n 5 4). There were 24 validated depression screening tools assessed, including abbreviated and modified versions (table 2). Index tests were self-administered or administered by trained staff, depending on the nature of the tool. The gold standard was always administered in person by a trained professional. The most frequently used gold standard was the DSM. While data were extracted for all tools, only the 15-item Geriatric Depression Scale (GDS-15), Beck Depression Inventory (BDI) I/Ia, Unified Parkinson's Disease Rating Scale (UPDRS), and Montgomery-Åsberg Depression Rating Scale (MADRS) provided sufficient data for meta-analysis (table 1). The BDI-I and BDI-Ia were pooled, given they have similar questions and scoring. The only difference between them is the BDI-Ia collapsed multiple optional answers, each with the same score to one single answer. 30 Prior studies have identified it is reasonable to collapse the 2 versions. 30 Most studies excluded patients with dementia on the basis of a Mini-Mental State Examination (MMSE) score ,23-24 or DSM diagnosis of dementia. There were only 3 studies that did not exclude patients with dementia 29, 31, 32 ; in those that did not exclude dementia, the mean or median MMSE was .24 and no studies included persons with MMSE scores below 7.
Pooled prevalence. The pooled prevalence of major depression across 15 unique populations (n 5 2,028) was 22.9% (95% CI 18.1-27.7) (table 1). There was considerable heterogeneity between studies (I 2 5 86.7%; p , 0.001). The prevalence estimate did not change when recalculated excluding the one study that included patients with PD with dementia. 29 The prevalence of major and minor depression was 31.3% (95% CI 21.1-41.6) across 8 studies and 1,201 patients. This estimate also had heterogeneity (I 2 5 94.1%; p , 0.001). We were unable to use several demographic covariates in the final analysis due to inconsistent reporting (e.g., dementia or disease severity) or if the variable was homogeneous (e.g., clinic location). Stratified and univariate meta-regression analyses were performed on prevalence for the variables interview type and continent. These analyses were underpowered (n , 10, per subgroup) to detect any difference 27 and are thus not reported.
Tools. The estimates reported for diagnostic accuracy are for major depression, as this was consistently reported (table 2) . Data from 21 studies were included in the qualitative synthesis (table 1). One of the largest studies 33 (n 5 229) examined 9 depression screening tools and determined the GDS-30 was the most accurate and convenient tool for use (sensitivity 72% and specificity 82%). The Patient Health Questionnaire (PHQ) is a commonly used tool, which has been validated among patients with PD within 3 separate studies (sensitivities ranging from 50% to 100%; specificities 80%-93%). 28, [33] [34] [35] Another tool was the Hamilton Depression Rating Scale (HDRS), including 24-, 21-, 17-, and 6-item versions across 6 studies. 33, [36] [37] [38] [39] [40] This is a commonly used clinician rating tool with reported sensitivities of 75%-100% and specificities ranging from 71% to 99%. There were 5 studies that reported accuracy estimates for the HDRS-17; however, 3 of these studies had overlapping populations, 37,40,41 thus estimates could not be pooled. Only the largest cohort from these 3 40 
is reported in the summary table. Other tools reported in single studies include National Institute for Health and Clinical Excellence, Edinburgh Depression Scale (EDS)/EDS brief, Zung Depression Rating Scale, Hospital Anxiety and Depression Scale, Beck Depression Inventory-II, Cornell Scale for Depression in Dementia (CSDD), Center for Epidemiologic Studies Depression Rating
Scale-Revised, and Inventory of Depressive Symptoms (IDS)-Self-report and IDS-Clinician. The reported sensitivities for these tools vary from 58% to 100% and specificities from 60% to 93% (table 1) .
The GDS-15. Six studies used the GDS-15, a selfrating tool for major depression. This tool had a pooled sensitivity of 0.81 (95% CI 0.64-0.91; I 2 5 75.86; p , 0.0001) and specificity of 0.91 (95% CI 0.87-0.94; I 2 5 60.87; p 5 0.03) ( figure  2A ). The PLR was 9.05 (95% CI 6.46-12.67; I 2 5 0; p 5 0.41) and the NLR was 0.21 (95% CI 0.10-0.42; I 2 5 79.59; p 5 0.01). An SROC curve was generated to visualize the relationship between sensitivity and specificity across the 6 pooled studies with an AUC of 0.94 (95% CI 0.91-0.96). The Fagan plot for this tool found a posttest probability for confirming depression of 73% and a posttest probability of ruling out depression of 6% (figure e-1A). Only 3 studies reported estimates for use of the GDS-15 to detect major and minor depression; hence there were insufficient studies to pool. 28, 35, 36, 39, 42, 43 For the GDS-15, cutoff points 5-9 were amenable to meta-analysis for major depression (table e-2). The cutoff of 5 had the highest sensitivity at 0.91 (95% CI 0.83-1.00; I 2 5 0; p 5 0.94; n 5 3), but the lowest specificity at 0.71 (95% CI 0.66-0.77; I 2 5 0; p 5 0.61; n 5 3). The cutoff of 6 represented a balance of sensitivity and specificity-sensitivity 0.87 (95% CI 0.78-0.95; I 2 5 0; p 5 0.79) and specificity 0.88 (95% CI 0.85-0.92; I 2 5 76.9; p 5 0.005). The highest specificity was at a cutoff of 9 with a specificity of 0.93% (95% CI 0.90-0.96; 56 ; 20 min (30-item) 57 These questions are focused on cognitive symptoms and not somatic symptoms, to avoid any overlap with normal aging or comorbid disease changes. 50 There is no question about suicide. 28 
Beck Depression Inventory 58
BDI-I or Ia (n 5 4); BDI-II (n 5 1)
21
Self Yes 5-10 min 57 Versions 1 and 1A are similar in their overall design and questions, with some changing in wording to avoid double negatives. 59 Version 2 was redesigned to fit with the DSM-IV criteria. The items cover cognitive, affective, behavioral, vegetative, and somatic symptoms. 59 
Montgomery-Åsberg Depression Rating Scale 60
MADRS (n 5 4); MADRS-Mod (n 5 1)
10 Clinician Yes 15-20 min 56 Can be used to screen, measure the severity, and specifically change in depression. 60 Covers the DSM criteria with the exception of psychomotor retardation and agitation. 60 Focused on psychological symptoms. 56 
Hamilton Depression Rating Scale or Inventory 54
HDRS-24 (n 5 1); HDRS-21 (n 5 2); HDRS-17 (n 5 3); HDRS-8 (n 5 1); HDRS-6 (n 5 1); HDI a (n 5 1) A semi-structured interview with a focus on nonsomatic symptoms. 56 It can measure severity of depression and changes during treatment. 54 Hamilton Depression Inventory is the self-rating version of the HDRS, available in the 17-item version. 36, 54 Unified Parkinson's Disease Rating Scale Part 1 61 UPDRS (n 5 4) 4 Self Yes 3 min 33 The UPDRS is a comprehensive tool for the overall assessment of PD and disability. There are 4 main sections to this tool, focused on mood, activities of daily living, motor symptoms, and complications of therapy. The first part of the tool focuses on mood and behavior, which includes one item on depression that is rated in severity from 1 to 4. 31, 42 Patient Health Questionnaire 52 PHQ 2-item (n 5 1); PHQ 9-item (n 5 3) 2; 9 Self No ,5 min 57 A scale based on the DSM-IV diagnostic criteria for depression and can monitor the severity of depressive symptoms. The PHQ-2 is the first 2 questions (depressed mood and anhedonia) of the PHQ-9 and has been demonstrated to be effective as a brief rating tool. 34, 35 National Institute for Health and Clinical Excellence 53 NICE (n 5 1) 2 Self or clinician No Very brief Created to screen groups at high risk of depression, with 2 items focused on the symptoms of low mood and anhedonia. 43 
Edinburgh Depression Scale 62
EDS (n 5 1); EDS brief (n 5 1)
10 Self No 5 min 57 Designed for depression in the postnatal period. However, a focus on cognitive and affective symptoms vs the somatic symptoms makes it appealing in other circumstances. 63 Zung Depression Rating Scale 64 SDS (n 5 1) 20 Self No 10 min 57 This tool is a 20-item scale, which focuses on affective, somatic, and psychological symptoms of depression. Each item is rated for severity based on frequency of symptoms. 51
Hospital Anxiety and Depression Scale 65
HADS (n 5 1) 14 Self Yes ,5 min 57 Examines 7 items in each of depression and anxiety, which exclude somatic symptoms. For depression, the questions are focused on anhedonia. 57 
Cornell Scale for Depression in Dementia 66
CSDD (n 5 1) 19
Clinician No 30 min 57 The CSDD is a tool designed to detect depression in patients with dementia, by including a proxy in the scales rating. 66 This is completed after a clinician-based interview with the patient and proxy. This tool has been validated in patients with and without dementia. 29, 66 Center for Epidemiologic Studies Depression Rating Scale 67 CESD (n 5 1) 20 Self No 10 min 57 Designed to assess depressive symptoms in epidemiologic studies, this tool has largely been used in research vs clinical settings. 57 Questions were selected from other depression scales, and focus on affective and somatic symptoms. 67 Inventory of Depressive Symptoms Clinician or Self Report 68 IDS-C (n 5 1); IDS-SR (n 5 1)
28
Clinician or self No 30-45 min 57 This tool covers the DSM-IV criteria for a major depressive episode. It also includes items on pain, anxiety, and atypical symptoms. This tool reports severity, duration, and frequency of symptoms. 57 Abbreviations: HDI 5 Hamilton Depression Inventory; PD 5 Parkinson disease. a Self Rated Version. I 2 5 36.9; p 5 0.21). Overall heterogeneity was low in the cutoff analysis.
The BDI-I/Ia. Four studies used the BDI-I/Ia, a selfrating tool. The pooled sensitivity was 0.79 (95% CI 0.61-0.90; I 2 5 44.65; p 5 0.14) and specificity was 0.85 (95% CI 0.79-0.90; I 2 5 22.67; p 5 0.27) ( figure  2B ). The pooled PLR was 5.41 (95% CI 3.83-7.63; I 2 5 0; p 5 0.66) and NLR was 0.25 (95% CI 0.13-0.48; I 2 5 0; p 5 0.41). 23, 42, 44, 45 An SROC curve of sensitivity and specificity demonstrated an AUC of 0.89 (95% CI 0.86-0.92). A Fagan plot showed a posttest probability for confirming disease of 62% and the reported posttest probability of ruling out disease of 7% (figure e-1B). 32, 33, 40, 45 An SROC curve demonstrated an AUC of 0.84 (95% CI 0.80-0.87). The Fagan plot showed a high posttest probability for confirming disease of 75% and the reported posttest probability of ruling out disease was 7% (figure e-1C).
The UPDRS. Four studies used the UPDRS, a self-rating tool, which has a pooled sensitivity of 0.72 (95% CI 0.64-0.79; I 2 5 0; p 5 0.65) and a specificity of 0.80 (95% CI 0.70-0.87; I 2 5 76.20; p 5 0.01) ( figure 2D) I 2 5 0; p 5 0.69), respectively. An SROC curve demonstrated an AUC of 0.89 (95% CI 0.86-0.92). 31, 33, 34, 42 The Fagan plot showed a posttest probability for confirming disease of 52% and the reported posttest probability of ruling out disease was 9% (figure e-1D).
Heterogeneity. Statistically significant heterogeneity was observed in the pooled estimates for the GDS and MADRS tool, and could be categorized as substantial. The proportion of heterogeneity likely due to threshold effect was 1.0, indicating the observed heterogeneity was related to different cutoffs used between studies. There were not enough data to pool within the same cutoffs for the UPDRS, MADRS, or BDI. Given the high proportion of heterogeneity due to threshold effect, tools that included only 3 studies were not pooled to avoid potentially biased estimates in the setting of the different cutoffs.
DISCUSSION This systematic review identified several valid tools for detecting depression in those experiencing PD. Three tools were sensitive and specific for identifying depression in PD: the GDS-15, BDI-I/ 1a, and MADRS. This enables clinics to examine patients in a valid and accurate manner, and to determine which patients need further assessment. The identification of several valid depression detection tools is ideal for providers, as this allows providers to tailor their choice of tool to specific clinical circumstances. The pooled prevalence of major depression was 22.9%, which approximates the findings from a 2008 meta-analysis that reported a prevalence of 24% for major depression in PD outpatient clinic settings (n 5 11). 5 It is notable that the prevalence of depression in PD varies with setting. The prevalence across all settings is 17%, and only 8% in population studies. 5 Therefore, the use of depression detection tools is likely best targeted to outpatient clinics, given that the pretest probability for depression is higher.
Findings suggest the GDS-15 would be an appropriate screening tool for depression in this population given its higher sensitivity. Also, the GDS has the highest AUC at 0.94 on the SROC analysis, indicating better global performance. The GDS also has the advantage of being available in the public domain (copyright free) and is a well-known brief self-rating tool that requires few resources to implement in a clinic. The GDS has also been translated into many different languages and has a collateral source version.
However, there is heterogeneity in the estimate across the best-reported cutoffs, attributable to the different thresholds compared. This variation is addressed by the meta-analysis of each cutoff, which revealed a cutoff of 5 as the most robust screening cutoff with the highest sensitivity (at 91%) and nonsignificant heterogeneity. Also, one study 28 in the GDS metaanalysis has a much lower reported sensitivity at 43% than the other studies, which contributed to the heterogeneity of the estimate pooled across the best cutoffs.
These findings coincide with those from a large study 33 that identified the clinical utility of the GDS. The GDS also addresses the concern of symptom overlap between depression and PD, given that the tool seeks to determine psychological and social dimensions rather than somatic dimensions, thereby reducing the potential influence of comorbid medical concerns on the outcome of the screening tool. 13 The BDI-I/Ia and MADRS are also valid tools. The BDI has a slightly lower sensitivity and PLR, making it less clinically discriminative. The main difficulty with the use of the BDI-I/Ia is that it is based on the older DSM-III criteria. 46 The MADRS tool has a higher PLR, but lower sensitivity, meaning it is less able to rule out disease. Additionally, the MADRS is clinicianrated rather than self-rated, which may limit its use in certain clinical settings due to time and resource constraints. The BDI and MADRS tools are variably controlled by copyright, making these less accessible tools for use clinically. 11 The UPDRS is a comprehensive PD assessment tool 34, 42 ; however, when the single item is isolated for depression screening, it appears to have lower discriminatory value. This is likely because a single question will not capture the varied features of depression. 33 The PHQ-9 is a commonly used depression rating tool that is based on the DSM-IV criteria, includes a question addressing suicidality, and is a self-rating tool that is in the public domain. 33, 35 However, across 3 studies, it demonstrated a wide range of sensitivity between 50% and 100%. One study reported a group of patients specifically with dementia, using the clinician CSDD. 29 Almost all other studies either excluded patients with dementia or included them in the total final estimate without reporting a subgroup.
Study limitations. Although we included studies from any outpatient location, the bulk of the included studies focused on movement disorders or neurology clinics. This is a potential source of bias in that patients presenting to these specialty clinics may have more severe illness, be older, be on more therapies, and potentially have a higher prevalence of comorbidities than their counterparts managed elsewhere. Additionally, there is an older age range within the included studies. It is possible that certain tools designed for an elderly population, such as the GDS, 47 may perform differently in a younger population of patients with PD. However, this was examined in 2007, and the GDS-15 demonstrated validity in nonelderly and elderly patients with PD. 48 There was a lack of reporting consistency or absence of important underlying population characteristics; for example, factors such as disease severity, patient assessment in "on" or "off" state, treatment for depression, or history of depression in the dataset. 11, 49 This meant that further subgroup analysis of the estimates based on these factors was not possible. Low study numbers for subgroup analysis precluded meaningful analysis based on factors such as interview type, location, and country. 5 Clinical utility. The use of a tool for detecting depression would assist clinicians in identifying those patients with PD who may be at risk and require further assessment. This review demonstrates the availability of 15 validated tools for the detection of depression. Tools are potentially more practical for ease of use in the clinic if they are self-rating, without copyright, and are short, such as the GDS. However, it is important that the tool chosen provides accurate and meaningful results to the specific context to base further clinical decisions.
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